Baricitinib protects β-cell function in new-onset type 1 diabetes
1. In this randomized controlled trial, the Janus kinase (JAK) inhibitor baricitinib was associated with preserved β-cell function compared to ...
Tag: Janus kinase (JAK) inhibitor
Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
1. After a 24-week treatment period, a significantly greater proportion of patients randomized to momelotinib had symptom scores reduced by ...
Tofacitinib increases cardiovascular and cancer risk in rheumatoid arthritis
1. Patients with rheumatoid arthritis (RA) treated with tofacitinib showed a higher risk of developing major adverse cardiovascular events and ...
Filgotinib effectively induces and maintains clinical remission in patients with ulcerative colitis
1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the ...
Upadacitinib non-inferior to adalimumab for psoriatic arthritis treatment
1. Janus kinase (JAK) inhibitor upadacitinib showed non-inferior efficacy in improving psoriatic arthritis compared to standard-of-care adalimumab. 2. High-dose upadacitinib ...
Upadacitinib may be superior to abatecept for refractory rheumatoid arthritis
1. Upadacitinib was superior to abatacept in achieving remission at 12 weeks for patients with rheumatoid arthritis refractory to biologic ...